Who imagined the industry could develop several COVID-19 vaccines and roll them out to millions in a matter of months? Manufacturers are rightly receiving a lot of credit, which Barry Silverstein thinks provides a rare opportunity to rebrand. But regulators have played a key role too – working at breakneck speed without cutting any corners in terms of safety. Here, the EMA explains how they did it. Elsewhere, we have a breakthrough in cold tumor drug discovery and a new project to get macromolecules across the intestinal epithelial barrier.
 

All the best, James Strachan, Deputy Editor

 
QUALITY & COMPLIANCE
Inside the EMA: How to Accelerate Vaccine Rollout – Safely
02/11/2021 | Stephanie Vine
Vaccine development for COVID-19 may have been rapid, but no one has scrimped on safety.
SMALL MOLECULES
Canceling Cancer’s Collaborators
02/10/2021 | James Strachan
Small-molecule Sb9 inhibitor targets both cancer and associated cells to suppress tumor growth in mice.
BUSINESS PRACTICE
Big Pharma: Heal Thyself
02/09/2021 | Barry Silverstein
Pharma hasn’t always covered itself in glory – but as the world scrambles for viable COVID-19 interventions, it has a rare opportunity to rebrand.
DOSAGE FORMS
Crossing the Border
02/08/2021 | Stephanie Vine
How can we get macromolecules across the intestinal epithelial barrier?
 
White Papers
Top five ways of improving the stability of your formulation

Formulation development is a critical activity for many industries, from pharmaceuticals, to paints and coatings. Read more

Exploring the relationship between molecular characteristics and bulk rheological properties of biodegradable polymers

Molecular and bulk characterization of PLA and PLGA samples using multi-detector GPC and rheometry. Read more

 
Special Promotions
There’s still time to save big on the 2021 PDA Annual Meeting

Join us at the 2021 PDA Annual Meeting, offered in a fully virtual format accessible from anywhere in the world. Gain practical solutions to improve your operations! Register by 28 February to save!

Webinar: galenIQ™ - Ask the Expert

galenIQ™ is a soluble filler-binder that is used to meet current challenges of the pharmaceutical and nutraceutical industries. Register for this webinar where experts talk about innovative ways galenIQ™ is used to answer to these needs.

We Need to Talk About Cell and Gene Therapy

Experts explain why the advanced therapy field must progress with the needs of the patient – as defined by the patient – in mind in The Medicine Maker Cell and Gene Therapy Supplement.

Learning from the Pandemic

Dominique Henry from Terumo believes highlights the importance of a unified global network and Shawn Walker from Johnson Matthey discusses pharma’s “smaller, safer – but more complex” – future. Learn more

Help us measure “Pandemic Impact” in Biopharma for a chance to win $100!

Take the “Pandemic Impact: Biopharma Trends 2021 Survey” now and you could win a $100 Amazon voucher (or a charitable donation, if preferred). Start Survey

 
Must-See Events Worldwide

We work with event organizers from all around the world to help bring the pharma industry together, from large congresses to intimate meetings that fit around a table. Discover some of the events that we partner with and and stay up-to-date with the latest developments.

Find out more